摘要
表皮生长因子受体(epidermal growth factor receptor,EGFR)是跨膜酪氨酸激酶受体,许多上皮肿瘤均有表达。厄罗替尼是喹唑啉类衍生物,可以选择性、可逆的抑制EGFR TK的活性。本文对厄罗替尼治疗非小细胞肺癌、胰腺癌、头颈部癌进行了综述。
The epidermal growth factor receptor （EGFR） is a transmembrane tyrosine kinase （TK） receptor that is frequently expressed in many epithelial tumors. Erlotinib ia a quinazoline derivative that selectively and reversibly inhibits the TK activity of EGFR. This review focuses on the clinical results available with erlotinib in the treatment of NSCLC, pancreatic cancer, head and neck cancer, and other types of malignancies.
出处
《癌症进展》
2009年第1期56-61,共6页
Oncology Progress
